[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
The Cutting Edge
July 2005

Improvement in Digital Flexibility and Dexterity Following Ingestion of Sildenafil Citrate (Viagra) in Limited Systemic Sclerosis

Author Affiliations
 

GEORGE J.HRUZAMDMICHAEL P.HEFFERNANMDSUMMER R.YOUKERMD

Arch Dermatol. 2005;141(7):831-833. doi:10.1001/archderm.141.7.831
REPORT OF A CASE

A 66-year old man with a 20-year history of limited systemic sclerosis and discoid lupus erythematosus–induced scarring alopecia presented to our clinic for follow-up. He had an antinuclear antibody ratio (Hep-2) of 1:80; homogeneous staining pattern; negative extractable nuclear antibody screen findings (anti-Sm, Anti-RNP, anti-Ro, and anti-La); anti–double-stranded DNA antibody value of 22 IU/L (normal, <50 IU/L); and negative anti-Scl-70 findings. He had no history of diabetes mellitus, ischemic heart disease, or peripheral vascular disease. His skin conditions had been stable for 6 years under treatment with 200 mg of hydroxychloroquine daily, 20 mg of omeprazole daily, 2% ketoconazole shampoo, clobetasol propionate as needed (intermittently) for scalp lesions of discoid lupus erythematosus, and 2 annual prostacyclin infusions in the winter season.

On examination, he was found to have sclerodactyly affecting all the digits of his hand with associated fixed flexion deformities of the small joints of the hands giving rise to the ”prayer sign” when the palms of his hands were opposed with maximum extension of the small joints of the hands (Figure 1). He was unable to clench his fist tightly without leaving spaces between the digits. He had a mouth opening distance of 4 cm and modified Rodnan score of 6. The modified Rodnan score comprises an aggregate skin score (0, normal; 1, thickened skin, able to pinch skinfold; 2, thickened skin, unable to pinch skinfold; or 3, thickened skin, unable to move skin) assessed in each of 17 areas (face, anterior chest, abdomen plus each limb individually [upper arm, forearm, dorsum of the hand, fingers, thighs, lower legs, dorsum of the foot]). The maximum potential score is 51.

Figure 1.
Flexion deformities before taking sildenafil citrate.

Flexion deformities before taking sildenafil citrate.

The distance between the corresponding first metacarpophalangeal joints of both hands was 41 mm. The distance between the corresponding proximal interphalangeal joints of both hands was 40 mm. There were no signs of proximal, truncal, or perioral skin sclerosis. Findings of general examination were otherwise unremarkable apart from scarring alopecia of the scalp.

CLINICAL CHALLENGE

Systemic sclerosis (or scleroderma) is broadly categorized into limited and diffuse cutaneous types based predominantly, but not solely, on the extent of sclerosis of the skin.1Limited systemic sclerosis is in general defined as the chronic presence of Raynaud phenomenon, peripheral skin involvement, calcification, telangiectasia, late onset of pulmonary hypertension, visible dilatation of the nail fold capillaries, and often (but not always) anticentromere antibodies. In contrast, diffuse cutaneous systemic sclerosis is in general characterized by a short interval (<1 year) between the onset of Raynaud phenomenon and development of truncal and peripheral skin changes, tendon friction rubs, internal organ complications (such as pulmonary fibrosis, renal failure, gastrointestinal disease, and myocardial involvement), and visible nail fold–capillary loop dropout. Patients with the diffuse condition often have positive anti–Scl-70 but negative anticentromere antibody findings. Patients with either limited or diffuse systemic sclerosis may also develop ulcerations of the finger pulp, focal calcification of the subcutaneous tissue, and in some cases digital autoamputation due to occlusive vasculopathy. Systemic sclerosis differs from mixed connective tissue disorder, which may involve sclerosis of the skin in association with features of dermatomyositis (or polymyositis) and/or systemic (but not discoid) lupus erythematosus, often associated with positive anti–U1-RNP findings.2

Ninety percent of patients with systemic sclerosis also have Raynaud phenomenon and associated abnormal cold sensitivity, although they appear to have normal reflex response to heat stimuli.37 Raynaud phenomenon can be ameliorated to varying degrees by keeping the hands protected from the cold and by using vasodilators.8 In contrast, sclerodactyly is usually slowly progressive. Progressive sclerosis of the dermis is accompanied by an increase in thickness of the skin in the digits.914 These changes alter the physical characteristics of the skin and lead to a reduction in the extensibility and elasticity of the skin, and as a result, there is gradual reduction and progressive loss of finger dexterity. This eventually leads to the development of fixed flexion deformities of the fingers and the prayer sign when both hands are held in opposition. Although many treatments have been used in systemic sclerosis, none has been clearly proven to improve hand function or to arrest the sclerotic process that leads to progressive loss of function.15

SOLUTION

Review of the patient’s systems was remarkable for a 20-year history of erectile dysfunction. For the preceding 5 years, this was successfully treated with intermittent use of sildenafil citrate (Viagra; Pfizer Inc, New York, NY). The patient reported the expected acute adverse effects of flushing and headache. In addition, he also noted reduction in frequency of Raynaud phenomenon and improved function and flexibility of his fingers starting 2 hours after ingestion of sildenafil. These effects would last up to 3 days after each time he used sildenafil.

Results of physical examination 12 hours after taking 50 mg of sildenafil citrate showed that the interdigital distances between the corresponding metacarpophalangeal and corresponding proximal interphalangeal joints of both hands were 25 and 28 mm, respectively (Figure 2), and the patient could clench his fist, leaving no spaces between the digits. His modified Rodnan score was 6, and his mouth opening distance was 6 cm. These improvements were lost after 3 days.

Figure 2.
Flexion deformities 12 hours after taking sildenafil citrate.

Flexion deformities 12 hours after taking sildenafil citrate.

COMMENT

Sildenafil is the first member of a new group of drugs that inhibit guanosine monophosphate–specific phosphodiesterase type 5 and are designed specifically for the treatment of erectile dysfunction.16,17 Sildenafil decreases the metabolism of cyclic guanosine monophosphate resulting in an increase in the level of nitric oxide, a potent vasodilator, which induces erection of the penis. Sildenafil is generally safe and has predictable adverse effects that occur in approximately 20% of patients.18 Headache, nasal stuffiness, and flushing are the most common adverse effects. It is recommended that caution be exercised in patients with concurrent ischemic heart disease, but in a large meta-analysis no excess risk of cardiovascular deaths was apparent.16 A single mortality due to sildenafil overdose has been reported.19

Nitric oxide metabolism is deranged in Raynaud phenomenon.20,21 Exogenous nitrates have been shown to ameliorate Raynaud phenomenon.21 In addition, genetic polymorphisms of endothelial nitric oxide synthetase have been reported in patients with scleroderma, which may predispose patients to develop scleroderma.22,23 Infusions of sodium nitroprusside (a nitric oxide donor for endothelium) and oral L-arginine (the endothelial substrate for nitric oxide) have been reported to cause vasodilatation,24 aid healing of digital ulcers in patients with scleroderma,25 and reduce laboratory-induced Raynaud phenomenon.26 However, studies using oral L-arginine report no apparent improvement in vasodilatation or Raynaud phenomenon.27,28

There has been 1 anecdotal report of improvement in Raynaud phenomenon and healing of digital ulcers with the use of sildenafil in 10 patients with connective tissue disease for whom treatment with calcium channel blockers had failed.29 In this report, no improvement in digital fixed flexion deformity or digital dexterity was mentioned.

In the present case, no improvement was noted in the modified Rodnan score, but objective improvement occurred in the flexibility of the patient’s hands and in the mouth-opening distance. These findings are not surprising given that the hand assessment contributes only a small part to the overall modified Rodnan score.30 We considered performing measurement with the Durometer (Type O, model 1700; Rex Gauge Company Inc, Buffalo Grove, Ill) to ascertain whether the observed effects resulted from softening of the skin, but the findings would be unreliable owing to the lack of flat surfaces and the presence of underlying bone in the digits.31 We thought it highly unlikely that sildenafil could affect digital sclerosus in such a short time, and indeed, the skin scores for the fingers in the modified Rodnan score remained unchanged after the ingestion of sildenafil. We therefore postulate that the improvement in digital dexterity and flexibility that we observed in our patient might have occurred as a result of alteration of the viscoelastic properties of the skin due to improved warming due to sildenafil-induced vasodilatation.32

Our observation suggests that 5-phosphodiesterase inhibitors may have a role in the treatment of Raynaud phenomenon and in improving digital dexterity in patients with sclerodactyly, particularly in women, for whom unwanted penile erection would not be an issue. The dose-response relationship of these compounds with respect to improvements in Raynaud phenomenon and digital dexterity is unknown. Further studies are required to confirm the potential benefits of sildenafil. In addition, newer, long-acting 5-phosphodiesterase inhibitors may offer a more convenient and sustained therapeutic response.

Article
Back to top
Article Information

Correspondence: Anthony Yung, MB,ChB, FRACP, Department of Dermatology, The Leeds General Infirmary, Great George St, Leeds, LS8 2QP, England.

Accepted for Publication: November 22, 2004.

Financial Disclosure: None.

Submissions

Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Electronic submissions must have all figures in TIFF format. Material should be accompanied by the required copyright transfer statement, as noted in “Instructions for Authors.” Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center, 14377 Woodlake Dr, Suite 111, Town and Country, MO 63017 (cuttingedge@lasersurgeryusa.com).

References
1.
LeRoy  ECBlack  CFleischmajer  R  et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 1988;15202- 205
PubMed
2.
LeRoy  EC Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes Curr Opin Rheumatol 1992;4821- 824
PubMed
3.
Goodfield  MJHume  ARowell  NR The effect of simple warming procedures on finger blood flow in systemic sclerosis Br J Dermatol 1988;118661- 668
PubMedArticle
4.
Engelhart  MSeibold  JR The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon Angiology 1990;41715- 723
PubMedArticle
5.
Engelhart  MKristensen  JK Raynaud's phenomenon: blood supply to fingers during indirect cooling, evaluated by laser Doppler flowmetry Clin Physiol 1986;6481- 488
PubMedArticle
6.
Engelhart  M The effect of sympathetic blockade and cooling in Raynaud's phenomenon Clin Physiol 1990;10131- 136
PubMedArticle
7.
Geirsson  AJJonsson  GSAsgeirsdottir  LP Functional study of the dermal microcirculation in systemic sclerosis Scand J Rheumatol 1994;2373- 76
PubMedArticle
8.
Block  JASequeira  W Raynaud's phenomenon Lancet 2001;3572042- 2048
PubMedArticle
9.
Kalis  BDe Rigal  JLeonard  F  et al.  In vivo study of scleroderma by non-invasive techniques Br J Dermatol 1990;122785- 791
PubMedArticle
10.
Nikkels-Tassoudji  NHenry  FPierard-Franchimont  CPierard  GE Computerized evaluation of skin stiffening in scleroderma Eur J Clin Invest 1996;26457- 460
PubMedArticle
11.
Dobrev  HP In vivo study of skin mechanical properties in patients with systemic sclerosis J Am Acad Dermatol 1999;40436- 442
PubMedArticle
12.
Enomoto  DNMekkes  JRBossuyt  PMHoekzema  RBos  JD Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma J Am Acad Dermatol 1996;35381- 387
PubMedArticle
13.
Ishikawa  TTamura  T Measurement of skin elastic properties with a new suction device (II): systemic sclerosis J Dermatol 1996;23165- 168
PubMed
14.
Ballou  SPMackiewicz  ALysikiewicz  ANeuman  MR Direct quantitation of skin elasticity in systemic sclerosis J Rheumatol 1990;17790- 794
PubMed
15.
Sapadin  ANFleischmajer  R Treatment of scleroderma Arch Dermatol 2002;13899- 105
PubMedArticle
16.
Fink  HAMac Donald  RRutks  IRNelson  DBWilt  TJ Sildenafil for male erectile dysfunction: a systematic review and meta-analysis Arch Intern Med 2002;1621349- 1360
PubMedArticle
17.
Reffelmann  TKloner  RA Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease Circulation 2003;108239- 244
PubMedArticle
18.
Lim  PHMoorthy  PBenton  KG The clinical safety of Viagra Ann N Y Acad Sci 2002;962378- 388
PubMedArticle
19.
Tracqui  AMiras  ATabib  ARaul  JSLudes  BMalicier  D Fatal overdosage with sildenafil citrate (Viagra): first report and review of the literature Hum Exp Toxicol 2002;21623- 629
PubMedArticle
20.
Matucci Cerinic  MKahaleh  MB Beauty and the beast: the nitric oxide paradox in systemic sclerosis Rheumatology (Oxford) 2002;41843- 847
PubMedArticle
21.
Anderson  MEMoore  TLHollis  SJayson  MIKing  TAHerrick  AL Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis Rheumatology (Oxford) 2002;41324- 328
PubMedArticle
22.
Fatini  CGensini  FSticchi  E  et al.  High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis Am J Med 2002;112540- 544
PubMedArticle
23.
Schlez  AKittel  MBraun  SHafner  HMJunger  M Endothelium-dependent regulation of cutaneous microcirculation in patients with systemic scleroderma J Invest Dermatol 2003;120332- 334
PubMedArticle
24.
Freedman  RRGirgis  RMayes  MD Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma Lancet 1999;354739
PubMedArticle
25.
Rembold  CMAyers  CR Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon Mol Cell Biochem 2003;244139- 141
PubMedArticle
26.
Agostoni  AMarasini  BBiondi  ML  et al.  L-arginine therapy in Raynaud's phenomenon? Int J Clin Lab Res 1991;21202- 203
PubMedArticle
27.
Khan  FLitchfield  SJMcLaren  MVeale  DJLittleford  RCBelch  JJ Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon Arthritis Rheum 1997;40352- 357
PubMedArticle
28.
Khan  FBelch  JJ Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation J Rheumatol 1999;262389- 2394
PubMed
29.
Lichtenstein  JR Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al Arthritis Rheum 2003;48282- 283
PubMedArticle
30.
Furst  DEClements  PJSteen  VD  et al.  The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis J Rheumatol 1998;2584- 88
PubMed
31.
Falanga  VBucalo  B Use of a durometer to assess skin hardness J Am Acad Dermatol 1993;2947- 51
PubMedArticle
32.
Ryan  TJ Vibration: good or bad? Clin Exp Dermatol 1981;6179- 189
PubMedArticle
×